

# 통년성 알레르기성 비염에서 리보스틴®(Levocabastine) 국소분무제 치료에 대한 임상 효과(단독 개방 실험)

가

조진희 · 이동희 · 권용식 · 조주은 · 윤희로 · 서병도

## Clinical Evaluation of Livostin® (Levocabastine) in the Treatment of Perennial Allergic Rhinitis(Open Single Center Clinical Trial)

Jin Hee Cho, MD, Dong Hee Lee, MD, Yong Sig Kwun, MD,  
Ju Eun Cho, MD, He Ro Yoon, MD and Byung Do Suh, MD

Department of Otolaryngology-Head and Neck Surgery, College of Medicine,  
The Catholic University of Korea, Seoul, Korea

### - ABSTRACT -

**Background & Objectives** : The new H1-receptor antagonist Livostin®(Levocabastine) is one of the most potent antihistamine available. Its effects also are known to be very specific, not displaying other systemic side effects. And it protects against allergen-induced nasal symptoms. This study was carried out to evaluate the efficacy of Livostin®(Levocabastine) in the treatment of allergic rhinitis. Also this study was one of clinical trials for medications which have been used for allergic rhinitis. **Subjects & Methods** : In our clinical study, trials have been performed with Livostin®(Levocabastine) nasal spray in 20 patients with allergic rhinitis at a dose of two puffs per nostril twice a day. The patient's and the investigator's evaluations of nasal symptoms were assessed before intranasal application, 1 week, and 2 weeks after intranasal application of Livostin®(Levocabastine). **Results** : Both the patient's and the investigator's evaluations of nasal symptoms showed significant improvements after intranasal application of Livostin®(Levocabastine) ( $p < 0.05$ , respectively). There was no side effect during follow-up periods. The global evaluation showed that 60% of Livostin®(Levocabastine)-treated patients considered therapeutic efficacy to be excellent or good. **Conclusion** : It was suggested that Livostin®(Levocabastine) might be effective and safe for the treatment of perennial allergic rhinitis. (*J Clinical Otolaryngol* 1999;10:46-52)

**KEY WORDS** : Livostin®(Levocabastine) · Allergic rhinitis · Topical antihistamine.

### 서 론

가 , , , 가 , 가  
: 1998 9 1  
: 1999 4 10  
: , 137 - 040 505 IgE  
가 : (02) 590 - 1512, 2764 · : (02) 595 - 1354  
E - mail : entcho@cmc.cuk.ac.kr

:  
 1. : 12  
 2. MAST(multiple allergosorbent test) :  
 3. :  
 , 가 ,

Livostin®(Levocabastine) (-) - {3S- [1(cis), 3, 4 ]} - 1 - [4 - cyano - 4 - (4 - fluorophenyl) cyclohexyl] - 3 - methyl - 4 - phenyl - 4 - piperidinecarboxylic acid monohydrochloride

<sup>3)</sup>  
 H1  
 가  
<sup>1)4)</sup> Livostin (Levocabastine) 12  
 65  
<sup>5)6)</sup>  
 1.  
 2. 2  
 3. 2  
 4. 3  
 5. 3  
 6. 가  
 7.  
 8.  
 9.

연구방법  
 가  
 Livostin® 가 1  
 (Levocabastine) 가 Livostin® (Levocabastine) 2 1 2

**연구대상 및 방법**

연구대상  
 1997 7 1998 2 가  
 , 가  
 20 3 가  
 가 7 가  
 가 (2 ), Livostin®(Levocabastine)  
 7 가 (3 ). 가

가 가 2. :

10 가 1 (+)

1. MAST : Dermatophagoides pteronissinus, Dermatophagoides farinae, house dust, cat & dog dander, cockroach

3. : ECP(eosinophilic cationic protein) IgE

ECP 350/100/mm<sup>3</sup> IgE 20 kU/L

15

가 가 (Table 1).

( × ) 가

1 , 2 , 3

3 mm 가

MAST class 2 가

가

**Table 1.** Criteria of scoring for each symptom

Symptom	Score	Degree	Change of symptom score
Rhinorrhea	0	Absent	No symptom
	1	Mild	1 - 4 episodes per day
	2	Moderate	5 - 10 episodes per day
	3	Severe	More than 10 episodes per day
Sneezing	0	Absent	No symptom
	1	Mild	1 - 4 episodes per day
	2	Moderate	5 - 10 episodes per day
	3	Severe	More than 10 episodes per day
Itching	0	Absent	No symptom
	1	Mild	Nasal breathing
	2	Moderate	Moderately disturbing
	3	Severe	Severely disturbing
Stuffiness	0	Absent	No symptom
	1	Mild	Nasal breathing
	2	Moderate	Sometimes mouth breathing
	3	Severe	Frequent mouth breathing





Livostin<sup>®</sup> (Levocabastine) 가  
 가  
 가  
 가  
 Livostin<sup>®</sup> (Levocabastine) H1 가  
 cromolyn sodium 가 가 가  
 terfenadine (Seldane<sup>®</sup>) 가 가 가  
 60% ,<sup>17)</sup> Dahl 55%, Ja-  
 ens 60%, Vermeulen Mercer 72%  
 Livostin<sup>®</sup> (Levocabastine) 가  
 cetirizine (Zyrtec<sup>®</sup>), azelastine 가  
 Azeptin<sup>®</sup> Livostin<sup>®</sup> (Levocabastine) 2 가 가  
 1~2 가  
 60~80% 가  
 1~2 µg/L 가  
 Livostin<sup>®</sup> (Levocabastine) 가  
 Livostin<sup>®</sup> (Levocabastine) 가  
 Livostin<sup>®</sup> (Levocabastine) 가 60% 가  
 Livostin<sup>®</sup> (Levocabastine) 가  
 Livostin<sup>®</sup> (Levocabastine) 가

**결 론**

중심 단어 :

### REFERENCES

- 1) Dahl R, Pedersen B, Larsen B. *Intranasal levocabastine for the treatment of seasonal allergic rhinitis: A multicentre, double-blind, placebo-controlled trial.* *Rhinology* 1995;33:121-5.
- 2) Knight A. *The role of levocabastine in the treatment of allergic rhinoconjunctivitis.* *Br J Clin Pract* 1994;48:139-43.
- 3) Awouters F, Niemegeers CJ, Jansen T, Megens AA, Janssen PA. *Levocabastine: Pharmacological profile of a highly effective inhibitor of allergic reactions.* *Agents Actions* 1992;35:12-8.
- 4) Janssens MM, Vanden Bussche G. *Levocabastine: An effective topical treatment of allergic rhinoconjunctivitis.* *Clin Exp Allergy* 1991;21 (Suppl 2):29-36.
- 5) Dechant KL, Goa KL. *Levocabastine: A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.* *Drugs* 1991;41:202-24.
- 6) Noble S, McTavish D. *Levocabastine: An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.* *Drugs* 1995;50:1032-49.
- 7) Vermeulen J, Mercer M. *Comparison of the efficacy and tolerability of topical levocabastine and sodium cromoglycate in the treatment of seasonal allergic rhinoconjunctivitis in children.* *Pediatr Allergy Immunol* 1994;5:209-13.
- 8) Heykants J, Van Peer A, Van de Velde V, Snoeck E, Meuldermans W, Woestenborghs R. *The pharmacokinetic properties of topical levocabastine: A review.* *Clin Pharmacokinet* 1995;29:221-30.
- 9) Janssens MM. *Levocabastine: A new topical approach for the treatment of paediatric allergic rhinoconjunctivitis.* *Rhinology* 1992;13 (Suppl):39-49.
- 10) Bachert C, Wagenmann M, Vossen-Holzenkamp S. *Intranasal levocabastine provides fast and effective protection from nasal allergen challenge.* *Rhinology* 1996;34:140-3.
- 11) de Graaf-in't Veld T, Garrelds IM, van Toorenbergen AW, Mulder PG, Gerth van Wijk R, Boegheim JP. *Effect of topical levocabastine on nasal response to allergen challenge and nasal hyperreactivity in perennial rhinitis.* *Ann Allergy Asthma Immunol* 1995;75:261-6.
- 12) van de Heyning PH, van Haesendonck J, Creten W, Rombaut N. *Effect of topical levocabastine on allergic and non-allergic perennial rhinitis: A double-blind study, levocabastine vs placebo, followed by an open, prospective, single-blind study on beclomethasone.* *Allergy* 1988;43:386-91.
- 13) Elwany S, Bassiouny M. *Topical levocabastine for the treatment of perennial allergic rhinitis.* *J Laryngol Otol* 1997;111:935-40.
- 14) Merkus FW, Schusler-van Hees MT. *Influence of levocabastine suspension on ciliary beat frequency and mucociliary clearance.* *Allergy* 1992;47:230-3.
- 15) Pazdrak K, Gorski P, Ruta U. *Inhibitory effect of levocabastine on allergen-induced increase of nasal reactivity to histamine and cell influx.* *Allergy* 1993;48:598-601.
- 16) Bende M, Pipkorn U. *Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis.* *Allergy* 1987;42:512-5.
- 17) Min YG, Lee CH, Jung HW, Kim CD, Suh JH, Chung DH, et al. *Efficacy of topical levocabastine in the treatment of allergic rhinitis.* *Korean J Rhinol* 1996;3:58-64.